Clinical Treatment Recommendation
Developing novel radiotherapy approaches and recommendations, guided by clinical expertise to maximize patient outcomes and clinical impact.
WG5. Clinical Treatment Recommendation
80
Members
Prof. Sebastian Brandner
WG Leader
Dr. Alkinoos Athanasiou
WG Co-Leader
Clinical Research
Category
Clinical Treatment Recommendations (Theme 5): This theme focuses on advancing therapeutic strategies in radiotherapy (RT) through the integration of radiomics and multimodal omics. The overarching goal is to refine pathological grading and improve precision in treatment. A critical objective is to differentiate between low-risk of growth (LRG) and high-risk of growth (HRG) patient groups, enabling a “Wait and See” monitoring strategy for low-risk cases while ensuring timely intervention for high-risk patients.
Among HRG patients, treatment strategies vary: (1) high-grade patients may require immediate surgery and/or RT; (2) low-grade tumours with low recurrence risk (LRR) may benefit from continued observation; while (3) low-grade tumours with high recurrence risk (HRR) may require aggressive RT protocols and closer follow-up.
The integration of radiomics, blood-based biomarkers, and genotypic profiling — supported by AI/ML frameworks — is anticipated to improve tumour grading precision and enable personalized therapy. Additionally, predictive models for brain metastasis prognosis have strong potential for incorporation into clinical RT practice.
The emerging Tumour Geometry Model (TGM) will be applied to optimize RT, including dose painting and beam shaping, to maximize tumour cell eradication. Furthermore, Stereotactic Single-Shot Radiotherapy (SSRT), although still in early stages, shows promise for clinical transformation. This Action will contribute to the development of evidence-based protocols and guidelines for SSRT application according to patient stratification and prognostic biomarker profiles.
Objectives
To improve patient outcomes through personalized medicine research. Relevant to RCO5, RCO4, RCO3
Tasks
T5.1 Improve the state-of-the-art and good practices in RT optimalisation; T5.2 Establish network of clinicians leading investigator-initiated trial in brain tumors; T5.3 WG3 meetings
Activities
Involved in all MC and WG5 meetings including organizing a WG4/WG5-focused conference, contribute to annual and final reports, the final year conference; 2 peer reviewed joint publications, contribute to dissemination, exploitation, training schools.
Milestones
M5.1: Mid-term report in (month 25);
M5.2: WG4/WG5 conference in (month 34).